vaccine

Monitoring vaccine safety in a nationwide adult Measles-Rubella immunization campaign

Year: 
2004
Author (s): 

Badilla X1, Morice A2, Machado V1, vila ML3, Murillo J4, Vieto E5, Reef S6, Castillo-Solrzano C7 1 Epidemiology Analysis and Surveillance Program, Social Security System, Costa Rica, 2 National Institute for Research and Training in Health and Nutrition (INCIENSA), Costa Rica 3 National Children Hospital (HNN), Costa Rica 4 National Center for Drug Surveillance, Social Security System, Costa Rica 5 National Blood Bank, Costa Rica 6National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 7 Expanded Program on Immunization, Pan American Health Organization, Washington, D.C.

Presenter (s): 

Pandemic Influenza Vaccine Effectiveness in Europe in 2009-10: Results of I-MOVE Multicentre Case-Control Study

Background: Following the emergence of the 2009 pandemic influenza A(H1N1) virus, monovalent influenza vaccines were developed and marketed in Europe. Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project, we estimated the pandemic influenza vaccines effectiveness (PIVE) using sentinel general practitioners (GP) influenza surveillance networks in seven European countries.

Year: 
2009
Author (s): 

Anne-Sophie Barret, E. Kissling, M. Valenciano, JM. Cohen, B. Oroszi, C. Rizzo, B. Nunes, D. Pitigoi, A. Larrauri, A. Mosnier, JK. Horvath, J. O?Donnell, A. Bella, R. Guiomar, E. Lupulescu, C. Savulescu, BC. Ciancio, P. Kramarz, A. Moren

Presenter (s): 
Ms. Anne-Sophie Barret
Syndicate content